Get the Stockscreener App
87.87
0.37%
0.32
After Hours:
87.87
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $87.87, with a volume of 944.83K.
It is up +0.37% in the last 24 hours and down -1.29% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$87.55
Open:
$87.17
24h Volume:
944.83K
Relative Volume:
0.59
Market Cap:
$43.30B
Revenue:
$9.93B
Net Income/Loss:
$1.12B
P/E Ratio:
39.05
EPS:
2.25
Net Cash Flow:
$1.58B
1W Performance:
-4.34%
1M Performance:
-1.29%
6M Performance:
-3.53%
1Y Performance:
-6.34%
1-Day Range:
$86.20
$87.92
1-Week Range:
$86.20
$91.61
52-Week Range:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
87.87 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
483.12 | 172.46B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
176.37 | 51.09B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
279.20 | 39.87B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.20B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
What markets is PTC Inc. expanding into Is Alcon Inc. stock a good long term investment optionValue Investing Picks For Beginners - jammulinksnews.com
How does Alcon Inc. generate profit in a changing economyPost Market Recommendation For 2025 - jammulinksnews.com
11 Best Medical Stocks to Buy According to Analysts - Insider Monkey
Alcon's (VTX:ALC) investors will be pleased with their notable 31% return over the last five years - simplywall.st
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health - Yahoo Finance
Alcon's TRYPTYR launches to the US market - Eyes On Eyecare
Alcon presenting new retina tools, clinical data at ASRS - Modern Retina
Published on: 2025-07-30 04:37:17 - metal.it
Published on: 2025-07-30 02:41:43 - metal.it
Alcon | 7/29/25 - ktnv.com
Momentum Indicator Shows Bearish Divergence in Alcon Inc.Weekly Stock Watch With Growth Focus Expanded - metal.it
Alcon Inc. May Stage Comeback if Support HoldsAnalysts Use RSI to Predict TECX’s Next MoveRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Eye Drops Market is evolving rapidly Through 2025 To 2032 | Alcon, - openPR.com
Is Alcon Inc. a growth stock or a value stockRapid wealth multiplication - jammulinksnews.com
How many analysts rate Alcon Inc. as a “Buy”Explosive portfolio gains - jammulinksnews.com
What are the latest earnings results for Alcon Inc.Discover high-growth stocks for your portfolio - jammulinksnews.com
What catalysts could drive Alcon Inc. stock higher in 2025Value Investing Review From AI Tools - jammulinksnews.com
Is it the right time to buy Alcon Inc. stockInvest smarter and grow your wealth faster - jammulinksnews.com
How volatile is Alcon Inc. stock compared to the marketFree Risk Assessment Services - jammulinksnews.com
What markets is Alcon Inc. expanding into Is TECX stock a good long term investment option - jammulinksnews.com
What are the technical indicators suggesting about Alcon Inc.Unprecedented profits - jammulinksnews.com
What institutional investors are buying Alcon Inc. stockDiscover investment plans that deliver results - jammulinksnews.com
Alcon Inc. Stock Analysis and ForecastExplosive capital gains - Autocar Professional
What analysts say about Alcon Inc. stockFree AI-Backed Trading Signals - Autocar Professional
What drives Alcon Inc. stock priceRapid return acceleration - PrintWeekIndia
Alcon's Strategic Acquisition of Lensar: A Game Changer in the FLACS Market - AInvest
LENSAR And Alcon: Assessing Potential Outcomes (NASDAQ:LNSR) - Seeking Alpha
Is Alcon Inc. a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Should You Continue to Hold Alcon (ALC)? - Insider Monkey
Alcon Helps with Back-to-School Prep - MyStateline
RBC Sticks With Alcon As Equipment Sales Lead Growth - Finimize
Swiss Stocks Slip As Roche And Alcon Weigh On The Index - Finimize
US Federal Trade Commission: FTC approves final order settling charges that Novartis AG’s acquisition of Alcon, Inc. was anticompetitive in U.S. eye care market - MLex
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):